[6-K] CytoMed Therapeutics Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

CytoMed Therapeutics Limited reported that its Executive Chairman and substantial shareholder, Mr. Choo Chee Kong, increased his shareholding through recent open‑market purchases of 105,824 shares.

According to the accompanying press release title, his effective ownership is now 21.95%. The update was furnished on a Form 6‑K dated October 22, 2025.

Insights

Corporate governance analyst

Insider buying disclosed; signals alignment but no direct financial impact.

CytoMed Therapeutics disclosed that its Executive Chairman purchased 105,824 shares in the open market. Insider purchases often indicate leadership’s confidence, but this filing is informational and does not change operating fundamentals by itself.

The press release title indicates his effective ownership at 21.95%. Any market impact depends on investor interpretation of insider activity; the filing does not specify pricing, timing beyond “recent,” or proceeds to the company.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On October 22, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing that its Executive Chairman and substantial shareholder, Mr Choo Chee Kong has increased his shareholding in the Company through recent open-market purchases of 105,824 shares.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Press Release dated October 22, 2025, titled: “CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%”

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: October 22, 2025	Title:	Director and Chairman

FAQ

What did CytoMed Therapeutics (GDTC) announce in this 6-K?

The company disclosed that its Executive Chairman, Mr. Choo Chee Kong, increased his shareholding via open-market purchases of 105,824 shares.

What is the Chairman’s effective ownership in GDTC after the purchases?

Per the press release title, his effective ownership is 21.95%.

When was this update provided by CytoMed Therapeutics (GDTC)?

The disclosure was furnished on October 22, 2025.

Does CytoMed Therapeutics receive proceeds from these purchases?

The filing states open-market purchases by the Chairman; it does not state any proceeds to the company.

Who is the insider buying GDTC shares?

The insider is Mr. Choo Chee Kong, Executive Chairman and substantial shareholder of CytoMed Therapeutics.